Navigation Links
GeoVax Labs' CEO Update Letter to Shareholders
Date:1/9/2012

and the U.S. Military HIV Research Program heralded a preventative vaccine that gave protection in non-human primates, a result similar to what GeoVax published earlier last year. This report confirmed the prime-boost approach plus the use of similar genetic material in the vaccine to induce a protective immune response. In essence, they have validated our concepts and added some good news to the field. Results like this give the industry hope that an effective HIV vaccine is not far from reality and bolster our confidence that we are on the right track.

Financing and Corporate Development

We continue to benefit from tremendous financial, operational, and technical support provided to us by the NIH and the HVTN. The HVTN, funded by the NIH, is the largest worldwide clinical trials network dedicated to development and testing of promising HIV/AIDS vaccines. To date, the HVTN has conducted and funded all of our clinical trials for the preventative version of our vaccine. In addition to this support from the HVTN, we are the recipient of a $20 million Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institute of Allergy and Infectious Disease (NIAID). This five-year grant spans a period from September 2007 through August 2012, providing financial support for the development of the GM-CSF adjuvanted version of our preventative vaccine.

While we are deeply appreciative of the generous governmental support we receive, it does not cover the cost of all of our activities. Hence, fundraising will continue to be a primary and critical focus for 2012, as it was in 2011. Through our efforts during 2010 and 2011 we have developed numerous contacts and raised our exposure profile among potential institutional investors which we believe will benefit us going forward. In addition to our equity financing efforts, we will continue to seek out additional opportunities for non-dilutive financing through govern
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
2. GeoVax Phase 2a Clinical Trial Completes Enrollment
3. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
4. GeoVax Labs, Inc. Announces Second Quarter Financial Results
5. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
6. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
7. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
8. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
9. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
10. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
11. GeoVax Labs Engages The Investor Relations Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... Products - Global Strategic Business Report" report to their ... for Anti-Adhesion Products in US$ Thousands by the following three ... Procedures. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ...
(Date:8/18/2014)... and HERZLIYA-PITUACH, Israel , Aug. ... OMX First North Premier, Stockholm : "IMNP"), ... that its application to list its common stock on the ... Market, a unit of the NASDAQ OMX Group. IMMUNE,s common ... Market at the opening of trading on August 21, 2014 ...
(Date:8/18/2014)... 2014 Reportlinker.com announces that a new market ... Russia Sinuscopes Market Outlook to 2020 ... Market Outlook to 2020 Summary ... 2020", provides key market data on the Russia Sinuscopes ... dollars, volume (in units) and average prices (in US ...
Breaking Medicine Technology:Global Anti-Adhesion Products - Strategic Business Report 2014 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4Russia Sinuscopes Market Outlook to 2020 2Russia Sinuscopes Market Outlook to 2020 3Russia Sinuscopes Market Outlook to 2020 4
... , SCOTTSDALE, Ariz. , Jan. 22 Matrixx Initiatives, ... financial results for the fiscal 2010 third quarter, ended December 31, ... January 25, 2010 . An earnings conference call will be held the ... AM ET . , To access the teleconference, please call (888) 452-4006 ...
... ... Called Ampyra, to Improve Walking for People With All Types of ... The U.S. Food and Drug Administration has approved the ... Therapeutics) for its ability to improve walking speed in people with ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2010 Financial Results 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
(Date:8/19/2014)... editorial published in this week,s JAMA highlights ... tools when considering how to treat patients. Written by ... Center and chair of pediatrics at Boston University School ... JAMA , the editorial examines results of a study ... an example of how doctors can often over-emphasize certain ...
(Date:8/19/2014)... Kars4Kids , a national nonprofit organization ... partnership with New York State Senator Gustavo Rivera to ... The giveaway will take place in conjunction with Rivera’s ... August 22. , “With a mission focused on ... children for school with the necessary supplies is imperative,” ...
(Date:8/19/2014)... August 19, 2014 “ Inbox Blueprint ... course designed to provide users with the tools necessary ... marketing techniques and strategies. The course which was ... of excitement throughout the internet marketing world. The commotion ... HonestyFirstReviews.com's Tiffany Hendricks prompting an updated review of the ...
(Date:8/19/2014)... (HealthDay News) -- Lupus and other rheumatic diseases ... seizures, which can delay a correct diagnosis for ... rheumatic diseases can also cause these types of ... Center in Maywood, Ill. Rheumatic disorders include ... soft tissues, such as lupus, systemic vasculitis and ...
(Date:8/19/2014)... 2014 In honor of National Dog Day on ... old furry friend by offering tips on caring for aging dogs. ... more. Because of this, dog owners need to realize the dog’s ... age, their needs change. They will not want to spend as ... used to. Because of this, pet owners should consider altering the ...
Breaking Medicine News(10 mins):Health News:Review of clinical treatment of bronchiolitis in infants reveals over-reliance on one test 2Health News:Backpack Giveaway Kars4Kids Partners with New York State Senator Gustavo Rivera to Prepare Bronx Students for New School Year 2Health News:Anik Singal’s “Inbox Blueprint” Review Released By HonestyFirstReviews.com 2Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:The Puppy Store Helps Pet Owners Care for Aging Dogs 2
... April 17 Even though suicide outranks homicide as ... death certificates thwart healthcare policymakers who want to create ... a WVU study shows."The Institute of Medicine ... have been diagnosed with a mental disorder, but death ...
... slumber , , FRIDAY, April 17 (HealthDay News) -- Over-the-counter ... with autism, a small U.S. study shows. , The ... with autism spectrum disorder, fragile X syndrome (FXS), or ... or a placebo for two weeks. After they completed ...
... partner and accomplished medical malpractice litigator Gary S. Genovese ... most recently of Martin, Lister, Alvarez & Genovese PLC ... and has had his cases featured in USA Today, ... He is well known for litigating cases throughout the ...
... where people are watching their spending, prescription discount card ... pricesWARRENSVILLE HEIGHTS, Ohio, April 17 The ... help provide its residents with some relief from the ... making free prescription drug discount cards available to city ...
... Recent economic events have led people to re-examine ... Many are feeling that it is time to get ... they are deciding to start their families now, instead ... is reflected in a growing number of couples who ...
... new German technology to process the conversion of medical records from ... ... April 17, 2009 -- Penny Imaging Exchange, Inc. (PIE) has acquired ... to digital form - the DRS Digitizer . With the ...
Cached Medicine News:Health News:Team Uncovers Discrepancy in Death Certificates Listing Suicide 2Health News:Melatonin May Ease Sleep Problems in Autistic Children 2Health News:Veteran Medical Malpractice Litigator Gary S. Genovese Re-Joins Conrad & Scherer LLP 2Health News:City of Warrensville Heights Residents Have Access to Easy-to-Use Prescription Drug Discount Card Launched Today 2Health News:Family Cocooning in the Face of Recession Leads to Expanded Business for Bay Area Fertility Doctor - Dr. Danielle Lane 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 3
... doubled Nd:YAG laser is mounted on Haag ... selected between 0.2 and 2.0 mJ. The ... and 700 microns. Knobs for laser energy ... on the laser head. The laser system ...
... Tango ophthalmic laser system provides two lasers ... and a photodisruptor for posterior capsulotomy and ... Nd:YAG producing pulsed 532 nm light. The ... nm. The appropriate laser can be easily ...
... Glaucoma Laser System features a patented technique ... glaucoma. It selectively targets pigmented cells and ... Selecta II is equipped with a Q-switch ... light, which induces the same cell replacement ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: